@gushamilton and team asked through observational study of COVID patients post discharge - 82% with long lasting symptoms (>8 months). Symptoms compared 1 month post vaccination to the unvaccinated.🧵 (1/)
When compared to matched unvaccinated participants (n=22), those who had receive a vaccine (n=44) had no worsening of symptoms. This is reassuring for people with long covid thinking about getting a vaccine. (2/)
In fact, a small overall improvement in Long Covid symptoms, with a decrease in worsening symptoms (5.6% vaccinated vs 14.2% unvaccinated) and increase in symptom resolution (23.2% vaccinated vs 15.4% unvaccinated)(p=0.035) was reported. This is encouraging 👍🏼 (3/)
What about the impact of different vaccines? No difference in response was identified between Pfizer-BioNTech (n=22) or Oxford-AstraZeneca (n=22) vaccines.
Looks like long haulers have good vaccine options available. (4/)
A limitation of this study (inherent to observational studies & stated by the authors) is that symptom recall may be influenced by receipt of vaccination (a placebo/nocebo effect). (5/)
We certainly need more studies like this to understand the impact of vaccines on #LongCovid.
Kudos to the authors 👏🏼 👏🏼
We also need to understand the underlying mechanisms of #longCOVID and #MECFS, to develop better diagnosis and therapy. (End)
This video shows that vaccines have helped some people with #longCOVID with their symptoms. While the numbers are still small in some groups, there are encouraging signs (also via @DanielGriffinMD).
I present my hypothesis on how vaccines might improve #LongCovid 🧵 (1/)
Back when I first learned about #longcovid in June 2020, I proposed 3 possible mechanisms. 1) Persisten viral reservoir 2) Viral fragments/remnants (RNA, protein) 'viral ghost’ driving inflammation 3) Autoimmune response induced by the infection (2/)
Since then, many studies have provided support for all of these. Viral reservoirs are found in tissues, viral RNA is found in non-respiratory tissues ⬆️ inflammation (@virusninja) 👇🏽, and diverse autoantibodies found in COVID patients (@Aaronmring). (3/)
How well do various vaccines reduce severe COVID disease & death? Awesome @YaleMed students, @dariusdariusdar, @ChaneyKalinich, @Larson_HaleighT & Caroline Valdez put together summary tables from vaccine trials. Remarkable ability of vaccines to ⬇️ severe/lethal COVID! 🧵(1/n)
The phase 3 Pfizer BioNTech two-shot mRNA vaccine trial data. All the tables here and below indicate the # COVID-related death in the vaccinated as the right-most column (which is ZERO). (2/n)
Top 10 most downloaded articles in 2020 includes our review in the @AnnualReviews Virology - “Seasonality of Respiratory Viral Infections” by @MiyuMoriyama et al! It’s free to download: arevie.ws/3aYt32Y
Here let’s highlight other relevant pieces on the same topic (1/n)
Just to recap, seasonal factors that drive respiratory tract viral infections are mainly these three;
1) ⬇️ Temperature 2) ⬇️ Humidity (esp. indoor) 3) ⬇️ Sunlight/Vitamin D
(2/n)
A twitter thread that demonstrates the importance of humidity on antiviral defense through mucociliary clearance measured by @Ericsongg. (3/n)
What is the relevance of viral load in #COVID19 disease severity? A very talented @YaleMSTP student @SilvaJ_C found that saliva viral load to be a better predictor of disease than nasopharyngeal viral load. Here is a thread to explain the findings. (1/n)
I preface by saying that numerous fantastic studies by many have demonstrated nasopharyngeal viral load to correlate with disease severity and mortality, while others do not find such correlation. Here are some of these studies. (2/n)
Being at @yale, the birthplace of #SalivaDirect and everything saliva bc of awesome colleagues like @awyllie13@NathanGrubaugh@VogelsChantal et al, we had access to both saliva and nasopharyngeal (NP) samples from the same patients to do direct comparisons. (3/n)
My first tweet of 2021 is going to be about 1 dose vs. 2 dose vaccine. I have tweeted in the past of the immunological advantages of a 2 dose vaccine. However, given the enhanced transmission variants on the rise, we need a modified strategy. (1/n)
We typically give vaccines in more than one dose to increase 1) quantity, 2) quality, 3) longevity of antibody responses. This holds true for most vaccines including mRNA vaccines. Here is what I tweeted about this before. (2/n)
However, the 2 dose vaccine with limited number of vaccine means only half the people getting vaccinated at this time. If the virus is spreading slowly, we want to do the right thing and give the most vulnerable 2 doses and others to wait. (3/n)
Inspired by this tweet by @TheMenacheryLab, I reached out to the wonderful colleagues at the @serimmune to see if the other mutations found in the B.1.1.7 variant would evade antibody responses generated by the wild type #SARSCOV2. (1/n)
According to this report, B.1.1.7 harbors non-synonymous mutations in the following viral genes, resulting in truncation, deletions and amino acid changes. Would these mutations result in evasion from antibodies generated by wild type virus? (2/n)
To probe this possibility, @serimmune used their technology platform based on bacterial display peptide libraries, next generation sequencing & machine learning to reveal antibody reactivity against WT and B.1.1.7 viral antigens. (3/n)